---
title: "Organovo (Nasdaq: ONVO) gives business update on its focus in developing treatments for inflammatory bowel disease."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/233457407.md"
description: "In San Diego on March 27, 2025, Organovo Holdings, Inc. (Nasdaq: ONVO) shared a business update. The company, a clinical stage biotech firm, specializing in innovative treatments for inflammatory bowel disease (IBD), detailed their recent developments."
datetime: "2025-03-27T12:27:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/233457407.md)
  - [en](https://longbridge.com/en/news/233457407.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/233457407.md)
generator: "portal-rs"
---

# Organovo (Nasdaq: ONVO) gives business update on its focus in developing treatments for inflammatory bowel disease.

In San Diego on March 27, 2025, Organovo Holdings, Inc. (Nasdaq: ONVO) shared a business update. The company, a clinical stage biotech firm, specializing in innovative treatments for inflammatory bowel disease (IBD), detailed their recent developments.

### Related Stocks

- [ONVO.US](https://longbridge.com/en/quote/ONVO.US.md)

## Related News & Research

- [Eupraxia Pharmaceuticals begins trading on Nasdaq Global Select Market after uplisting from Nasdaq Capital Market](https://longbridge.com/en/news/298315876.md)
- [Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of "Moderate Buy" by Brokerages](https://longbridge.com/en/news/298407524.md)
- [Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Recommendation of "Moderate Buy" by Brokerages](https://longbridge.com/en/news/298423186.md)
- [enGene (NASDAQ:ENGN) Given "Buy" Rating at HC Wainwright](https://longbridge.com/en/news/298348476.md)
- [Akebia Therapeutics (NASDAQ:AKBA) Earns Buy Rating from Analysts at Westpark Capital](https://longbridge.com/en/news/298343412.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**